Voluntary nationwide recall: Sucralfate (Nostrum – July)

Jul. 2025Pharmacy Updates

Nostrum Laboratories, Inc. is recalling all lots of Sucralfate Tablets USP 1 gram. Sucralfate is used for the prevention and treatment of certain stomach ulcers.

Nostrum Labs filed bankruptcy on Sept. 30, 2024. In connection with that filing, the company has ceased and shut down operations. Nostrum Labs is initiating a voluntary recall of Sucralfate Tablets USP 1 gram, all lots within expiry, as a result of the closures and discontinuation of its quality activities. This recall pertains only to Sucralfate Tablets USP 1 gram manufactured by Nostrum Labs after June 2023. No other Nostrum Labs products are affected by this recall. Using a product that may not meet quality standards means that the company is unable to confirm that the product has the correct identity, strength, quality, and purity characteristics.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Sucralfate, you should talk to your doctor before stopping the medication.

As of July 11, 2025, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.


Recent Announcements

Understanding available resources for substance misuse and addiction

Information available on the internet can be overwhelming when searching on the topic of substance misuse and addiction. UPMC Health Plan has a dedicated webpage containing information and links to treatment service options, harm reduction services, and other supports. The webpage includes local, state, and national resources to help streamline the search process for members and their families who may be experiencing challenges related to substance misuse and addiction, and for providers who may be looking for information on how to best support their patients.
Aug. 2025Important Notices

The importance of PRD forms for complex patients and staying updated on changes

Personal representative designation (PRD) forms are critical to the care process for patients and providers alike. Not only do PRDs support accurate, efficient, and compliant patient care—they also streamline administrative processes.
Aug. 2025Important Notices

Important announcement: UPMC Health Plan retires MP.PA.147

This communication is in regards to UPMC Health Plan Policy MP.PA.147 – Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older. UPMC Health Plan previously communicated that the prior authorization requirement under this policy would be paused until Sept. 1, 2025. However, policy MP.PA.147 has been retired, and this policy will no longer be implemented or active.
Aug. 2025Important Notices